Research Funds Bonanza Going Up in Smoke?

T he Senate's snuffing of anti-tobacco legislation last month also extinguished some optimism for increased science funding for fiscal year 1999, which begins Oct. 1, 1998. "It's definitely a setback," Mary Woolley, president of Research!America, admits. President Bill Clinton had earmarked some of the anticipated revenue from proposed increases in cigarette taxes to pay for a boost in biomedical research funding. Without that revenue, Research!America's goal of doubling biomedical research fu

| 3 min read

Register for free to listen to this article
Listen with Speechify
0:00
3:00
Share

T he Senate's snuffing of anti-tobacco legislation last month also extinguished some optimism for increased science funding for fiscal year 1999, which begins Oct. 1, 1998.

"It's definitely a setback," Mary Woolley, president of Research!America, admits. President Bill Clinton had earmarked some of the anticipated revenue from proposed increases in cigarette taxes to pay for a boost in biomedical research funding. Without that revenue, Research!America's goal of doubling biomedical research funding in five years becomes more difficult (P. Smaglik, The Scientist, 11[22]:1, Nov. 10, 1997). Even with higher cigarette taxes, that goal would have been challenging. Doubling research requires a 15 percent boost in the National Institutes of Health's budget from FY 1999 to FY 2003; President Clinton has requested an 8.4 percent increase for NIH in FY 1999--a figure that includes projected revenue from tobacco.

Some Republicans had been critical of the budgeting that anticipated cigarette revenue for research. ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

  • Paul Smaglik

    This person does not yet have a bio.

Published In

Share
May digest 2025 cover
May 2025, Issue 1

Study Confirms Safety of Genetically Modified T Cells

A long-term study of nearly 800 patients demonstrated a strong safety profile for T cells engineered with viral vectors.

View this Issue
Detecting Residual Cell Line-Derived DNA with Droplet Digital PCR

Detecting Residual Cell Line-Derived DNA with Droplet Digital PCR

Bio-Rad
How technology makes PCR instruments easier to use.

Making Real-Time PCR More Straightforward

Thermo Fisher Logo
Characterizing Immune Memory to COVID-19 Vaccination

Characterizing Immune Memory to COVID-19 Vaccination

10X Genomics
Optimize PCR assays with true linear temperature gradients

Applied Biosystems™ VeriFlex™ System: True Temperature Control for PCR Protocols

Thermo Fisher Logo

Products

The Scientist Placeholder Image

Biotium Launches New Phalloidin Conjugates with Extended F-actin Staining Stability for Greater Imaging Flexibility

Leica Microsystems Logo

Latest AI software simplifies image analysis and speeds up insights for scientists

BioSkryb Genomics Logo

BioSkryb Genomics and Tecan introduce a single-cell multiomics workflow for sequencing-ready libraries in under ten hours

iStock

Agilent BioTek Cytation C10 Confocal Imaging Reader

agilent technologies logo